A.R.T. Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

A.R.T. Advisors’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-27,800	Closed	-$292K	–	1892
2017 Q1	$292K	Sell	27,800 -43,400	-61%	-$462K	0.01%	1013
2016 Q4	$655K	Buy	+71,200	New	+$804K	0.04%	637
2016 Q3	–	Sell	-45,297	Closed	-$586K	–	1409
2016 Q2	$586K	Sell	45,297 -60,164	-57%	-$877K	0.03%	754
2016 Q1	$1.69M	Buy	105,461 +95,700	+980%	+$1.82M	0.08%	390
2015 Q4	$279K	Buy	9,761 +1,161	+14%	+$32.2K	0.01%	1084
2015 Q3	$244K	Buy	+8,600	New	+$317K	0.01%	1107
2015 Q1	–	Sell	-138,714	Closed	-$2.92M	–	1823
2014 Q4	$2.92M	Buy	138,714 +53,200	+62%	+$1.05M	0.11%	259
2014 Q3	$1.66M	Buy	+85,514	New	+$1.34M	0.08%	350
2014 Q2	–	Sell	-165,478	Closed	-$3.43M	–	1647
2014 Q1	$3.43M	Buy	+165,478	New	+$3.28M	0.18%	134
2013 Q4	–	Sell	-126,027	Closed	-$1.47M	–	1646
2013 Q3	$1.47M	Buy	+126,027	New	+$1.03M	0.08%	367

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

A.R.T. Advisors's INSY Position: Q2 2017 in Review

A.R.T. Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2017, closing a stake of 27,800 shares — an estimated $292K sold.

A.R.T. Advisors first reported a position in INSY in Q3 2013 and held it in 10 quarters. The position peaked at $3.43M in Q1 2014. 118 funds tracked by Wall St. Rank hold INSY as of Q2 2017.

A.R.T. Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
A.R.T. Advisors sold 27,800 Insys Therapeutics, Inc. shares in Q2 2017, an estimated $292K.
A.R.T. Advisors first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 10 quarters.
A.R.T. Advisors's Insys Therapeutics, Inc. position peaked at $3.43M in Q1 2014.
118 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2017.

Based on A.R.T. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.